Can-Fite BioPharma Ltd. - CANF
Detailed investor-level table based on 13F positions.
Methodology:
Market value and % of portfolio use SEC reported VALUE ($000).
For PUT/CALL positions this reflects reported underlying exposure, not premium cash paid/received.
Details.
Rows: 0
| Investor | History | Status | Shares held | Market value ($000) | % of portfolio | Previous % | Rank | Change in shares | % change in shares | Source | Date reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | History | No change | 32,533 | 96 | 0.0% | 0.0% | 1 | 0 | 0.0% | Q2 2026 | Sep 02, 2026 |
| RHUMBLINE ADVISERS | History | Added to | 19,443 | 42 | 0.0% | 0.0% | 2 | +2,010 | 11.53% | Q3 2026 | Nov 10, 2026 |
| JANE STREET GROUP, LLC | History | New | 13,324 | 29 | 0.0% | — | 3 | +13,324 | New | Q3 2026 | Nov 12, 2026 |
| GAMMA Investing LLC | History | New | 6,706 | 14 | 0.0% | — | 4 | +6,706 | New | Q3 2026 | Oct 08, 2026 |
| UBS Group AG | History | New | 2,739 | 6 | 0.0% | — | 5 | +2,739 | New | Q3 2026 | Nov 10, 2026 |
| CITIGROUP INC | History | New | 2,175 | 4 | 0.0% | — | 6 | +2,175 | New | Q3 2026 | Nov 04, 2026 |
| Avion Wealth | History | Closed out | 0 | 0 | — | — | — | -5 | -100.0% | Q3 2026 | Nov 03, 2026 |
| FIFTH THIRD BANCORP | History | No change | 150 | 0 | — | — | — | 0 | 0.0% | Q3 2026 | Nov 05, 2026 |
| WELLS FARGO & COMPANY/MN | History | No change | 59 | 0 | — | — | — | 0 | 0.0% | Q2 2026 | Aug 14, 2026 |
| MORGAN STANLEY | History | No change | 1 | 0 | — | — | — | 0 | 0.0% | Q2 2026 | Aug 13, 2026 |
| Activest Wealth Management | History | No change | 10 | 0 | — | — | — | 0 | 0.0% | Q3 2026 | Oct 15, 2026 |
| TD Waterhouse Canada Inc. | History | No change | 1 | 0 | — | — | — | 0 | 0.0% | Q3 2026 | Oct 16, 2026 |
| BFC Planning, Inc. | History | No change | 250 | 0 | — | — | — | 0 | 0.0% | Q2 2026 | Oct 29, 2026 |